Safety and efficacy of continuous glucose monitoring devices in individuals with diabetes undergoing hyperbaric oxygen therapy: a scoping review.

IF 0.8 4区 医学 Q4 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
Glen Katsnelson, Marcus Salvatori, George Djaiani, Elise Greer, Jordan Tarshis, Rita Katznelson
{"title":"Safety and efficacy of continuous glucose monitoring devices in individuals with diabetes undergoing hyperbaric oxygen therapy: a scoping review.","authors":"Glen Katsnelson, Marcus Salvatori, George Djaiani, Elise Greer, Jordan Tarshis, Rita Katznelson","doi":"10.28920/dhm55.2.164-172","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Continuous glucose monitoring devices (CGMs) have emerged as an effective approach to optimise glycaemic control for individuals living with diabetes mellitus. Despite CGMs offering improved patient satisfaction and quality of life, they have been primarily validated for outpatient and home use. This has posed a challenge for patients and providers who wish to incorporate CGMs into clinical settings such as hyperbaric oxygen therapy (HBOT). Those with advanced diabetes mellitus who have diabetic foot ulcers that are refractory to treatment are among the most prevalent users of HBOT. However, those who prefer to use their CGM during HBOT face uncertainty regarding the accuracy and safety of their device under hyperbaric conditions.</p><p><strong>Methods: </strong>The product specifications of commonly used CGMs were collated. In addition, a scoping review of the literature was conducted where Medline, Embase, and Scopus were searched for reports that assess the accuracy or safety of CGMs in hyperbaric conditions.</p><p><strong>Results: </strong>The product specifications of commonly used CGMs by Dexcom, Abbott, Medtronic, and Senseonics demonstrate a maximum validated pressure of approximately 106 kPa (1.06 atmospheres absolute). Our literature search identified five reports, of which four focused on accuracy and one focused on safety of CGMs in hyperbaric conditions. Treatments were conducted in multiplace chambers and cumulatively described 39 participants, of whom 12 have diabetes. Although heterogeneous in nature, the reports generally supported the safety and accuracy of CGMs in hyperbaric conditions.</p><p><strong>Conclusions: </strong>The safety and accuracy of using CGMs during HBOT warrants further investigation. CGMs have not been validated for repeated exposure to hyperbaric conditions and should not be used in oxygen pressurised monoplace chambers until further safety data is available. We provide practical recommendations for use of CGMs in multiplace chambers.</p>","PeriodicalId":11296,"journal":{"name":"Diving and hyperbaric medicine","volume":"55 2","pages":"164-172"},"PeriodicalIF":0.8000,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diving and hyperbaric medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.28920/dhm55.2.164-172","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Continuous glucose monitoring devices (CGMs) have emerged as an effective approach to optimise glycaemic control for individuals living with diabetes mellitus. Despite CGMs offering improved patient satisfaction and quality of life, they have been primarily validated for outpatient and home use. This has posed a challenge for patients and providers who wish to incorporate CGMs into clinical settings such as hyperbaric oxygen therapy (HBOT). Those with advanced diabetes mellitus who have diabetic foot ulcers that are refractory to treatment are among the most prevalent users of HBOT. However, those who prefer to use their CGM during HBOT face uncertainty regarding the accuracy and safety of their device under hyperbaric conditions.

Methods: The product specifications of commonly used CGMs were collated. In addition, a scoping review of the literature was conducted where Medline, Embase, and Scopus were searched for reports that assess the accuracy or safety of CGMs in hyperbaric conditions.

Results: The product specifications of commonly used CGMs by Dexcom, Abbott, Medtronic, and Senseonics demonstrate a maximum validated pressure of approximately 106 kPa (1.06 atmospheres absolute). Our literature search identified five reports, of which four focused on accuracy and one focused on safety of CGMs in hyperbaric conditions. Treatments were conducted in multiplace chambers and cumulatively described 39 participants, of whom 12 have diabetes. Although heterogeneous in nature, the reports generally supported the safety and accuracy of CGMs in hyperbaric conditions.

Conclusions: The safety and accuracy of using CGMs during HBOT warrants further investigation. CGMs have not been validated for repeated exposure to hyperbaric conditions and should not be used in oxygen pressurised monoplace chambers until further safety data is available. We provide practical recommendations for use of CGMs in multiplace chambers.

连续血糖监测装置在接受高压氧治疗的糖尿病患者中的安全性和有效性:一项范围综述。
简介:连续血糖监测装置(cgm)已成为糖尿病患者优化血糖控制的有效方法。尽管cgm可以提高患者满意度和生活质量,但它们主要用于门诊和家庭使用。这对希望将cgm纳入临床环境(如高压氧治疗(HBOT))的患者和提供者提出了挑战。那些患有难治性糖尿病足溃疡的晚期糖尿病患者是HBOT最普遍的使用者。然而,那些喜欢在HBOT期间使用CGM的人面临着高压条件下设备准确性和安全性的不确定性。方法:整理常用中药制剂的产品规格。此外,对文献进行了范围审查,在Medline、Embase和Scopus中检索评估高压氧条件下cgm准确性或安全性的报告。结果:Dexcom、雅培、美敦力和Senseonics常用的cgm产品规格显示,最大验证压力约为106 kPa(1.06大气压)。我们的文献检索确定了五份报告,其中四份侧重于准确性,一份侧重于高压氧条件下cgm的安全性。治疗在多个地方进行,总共描述了39名参与者,其中12名患有糖尿病。虽然性质不同,但报告普遍支持cgm在高压条件下的安全性和准确性。结论:在HBOT中使用cgm的安全性和准确性值得进一步研究。cgm还没有经过反复暴露在高压条件下的验证,在获得进一步的安全性数据之前,不应该在氧气加压的单一环境中使用。我们提供了在多地点腔室中使用cgm的实用建议。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Diving and hyperbaric medicine
Diving and hyperbaric medicine 医学-公共卫生、环境卫生与职业卫生
CiteScore
1.70
自引率
22.20%
发文量
37
审稿时长
>12 weeks
期刊介绍: Diving and Hyperbaric Medicine (DHM) is the combined journal of the South Pacific Underwater Medicine Society (SPUMS) and the European Underwater and Baromedical Society (EUBS). It seeks to publish papers of high quality on all aspects of diving and hyperbaric medicine of interest to diving medical professionals, physicians of all specialties, scientists, members of the diving and hyperbaric industries, and divers. Manuscripts must be offered exclusively to Diving and Hyperbaric Medicine, unless clearly authenticated copyright exemption accompaniesthe manuscript. All manuscripts will be subject to peer review. Accepted contributions will also be subject to editing.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信